



# SUMMARY

## Summary

The aim of this work was to develop new synthetic models for the type 3 active sites in copper proteins and get insight into the effect of auxiliary groups on the ligands on the activity of the complexes.

- ✚ Compartmental Schiff bases ligands were synthesized by condensation of dfc, dac, dap and bamnp with suitable biogenic amines, namely, tryptamine, histamine & pyridoxamine; N containing heterocyclic molecules such as N-aminoethyl piperazine, N-aminoethyl morpholine, N-aminoethyl pyrrolidine, 2-picoyl amine & tryptamine; and carbonyl compounds viz. 2-hydroxy-1-acetonaphthone, 1-hydroxy-2-acetonaphthone pyrrole-2-carboxaldehyde and 7-hydroxy-8-formyl-4-methyl coumarin. Homonuclear dicopper(II) complexes and heteronuclear copper(II)-zinc(II) complexes were synthesized using these ligands
- ✚ All ligands and complexes were characterized by various spectroscopic techniques such as UV-Vis and IR spectroscopies, mass spectrometry, elemental analysis and ESR spectroscopy.
- ✚ Crystal structures of representative complexes has been obtained.
- ✚ ESR spectra and magnetic properties of representative complexes suggest the presence of antiferromagnetic exchange between the copper(II) centers in the dicopper(II) complexes.
- ✚ SOD mimic activity of all synthesized ligands and complexes was studied by non-enzymatic (NADH-PMS-NBT) method to find their potential to dismutase superoxide.
- ✚ Ascorbic acid oxidase activity of all complexes was studied and the kinetic parameters determined.
- ✚ The catecholase activity of all complexes was studied for various o-diphenols as substrates, by varying parameters such as temperature, concentrations of substrate and catalysts. Michaelis-Menten approach was used to evaluate the potential of complexes as for functional models of catecholase.
- ✚ DNA and BSA binding studies of all synthesized compounds was carried out to find their efficacies to bind with the biomolecules using UV-Vis spectroscopy and fluorescence methods.
- ✚ Cytotoxic studies were carried out for selected copper(II) complexes on HepG2 cancer cell line.

The observations for all complexes are summarized in the tables given below:

### SOD mimic activity

Cat.	IC <sub>50</sub>	Dinuclear moiety	Endogenous bridge ligand	
<b>C5</b>	0.128	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(aminoethyl) morpholine
<b>C4</b>	0.242	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(aminoethyl) piperazine
<b>C8</b>	0.329	Cu-Cu	2,6-diacetyl-4-methylphenol	tryptamine
<b>C1a</b>	0.351	Cu-Cu	2,6-diformyl-4-methylphenol	Pyridoxamine
<b>C13</b>	0.385	Cu-Cu	2,6-diamiomethyl-4-nitrophenol	1-hydroxy-2-acetonaphthone
<b>C2a</b>	0.396	Cu-Cu	2,6-diformyl-4-methylphenol	tryptamine
<b>C15</b>	0.794	Cu-Cu	2,6-diamiomethyl-4-nitrophenol	2-formyl pyrrole
<b>C14</b>	0.925	Cu-Cu	2,6-diamiomethyl-4-nitrophenol	2-hydroxy-1-acetonaphthone
<b>C6</b>	1.157	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(aminoethyl) pyrrolidine
<b>C9</b>	1.5582	Cu-Cu	1,3-diaminopropan-2-ol	1-hydroxy-2-acetonaphthone
<b>C16</b>	1.923	Cu-Cu	2,6-diamiomethyl-4-nitrophenol	8-formyl-7-hydroxy-4-Methylcoumarin
<b>C10</b>	2.4163	Cu-Cu	1,3-diaminopropan-2-ol	2-hydroxy-1-acetonaphthone
<b>C2b</b>	4.02	Cu-Zn	2,6-diformyl-4-methylphenol	tryptamine
<b>C3a</b>	7.45	Cu-Cu	2,6-diformyl-4-methylphenol	histamine
<b>C1b</b>	7.66	Cu-Zn	2,6-diformyl-4-methylphenol	pyridoxamine
<b>C12</b>	13.1729	Cu-Cu	1,3-diaminopropan-2-ol	8-formyl-7-hydroxy-4-Methylcoumarin
<b>C3b</b>	208.1	Cu-Zn	2,6-diformyl-4-methylphenol	histamine

## Ascorbic Acid Oxidase activity

Cat.	$k_{cat}$ (h <sup>-1</sup> )	$E_a$ (kJ/mole)	Dinuclear moiety	Endogenous bridge ligand	
<b>C8</b>	725	70.1	Cu-Cu	2,6-diacetyl-4-methylphenol	tryptamine
<b>C5</b>	595	71.5	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(2-aminoethyl)morpholine
<b>C13</b>	367	60.9	Cu-Cu	2,6-diaminomethyl-4-nitrophenol	1-hydroxy-2-acetonaphthone
<b>C14</b>	363	68.3	Cu-Cu	2,6-diaminomethyl-4-nitrophenol	2-hydroxy-1-acetonaphthone
<b>C15</b>	360	63.1	Cu-Cu	2,6-diaminomethyl-4-nitrophenol	2-formyl pyrrole
<b>C6</b>	340	74.6	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(2-aminoethyl)pyrrolidine
<b>C2a</b>	334.9	65.4	Cu-Cu	2,6-diformyl-4-methylphenol	tryptamine
<b>C2b</b>	332	71	Cu-Zn	2,6-diformyl-4-methylphenol	tryptamine
<b>C1a</b>	332	70.4	Cu-Cu	2,6-diformyl-4-methylphenol	pyridoxamine
<b>C4</b>	321	77.4	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(2-aminoethyl)piperazine
<b>C16</b>	217	61.9	Cu-Cu	2,6-diaminomethyl-4-nitrophenol	8-formyl-7-hydroxy-4-methylcoumarin
<b>C10</b>	202	92.7	Cu-Cu	1,3-diaminopropan-2-ol	2-hydroxy-1-acetonaphthone
<b>C7</b>	202	79.0	Cu-Cu	2,6-diacetyl-4-methylphenol	2-picoylamine
<b>C9</b>	173	58.4	Cu-Cu	1,3-diaminopropan-2-ol	1-hydroxy-2-acetonaphthone
<b>C12</b>	80.9	27.0	Cu-Cu	1,3-diaminopropan-2-ol	8-formyl-7-hydroxy-4-methylcoumarin
<b>C1b</b>	75.5	71.8	Cu-Zn	2,6-diformyl-4-methylphenol	pyridoxamine
<b>C3b</b>	50.7	78.4	Cu-Zn	2,6-diformyl-4-methylphenol	histamine
<b>C3a</b>	37.3	77.6	Cu-Cu	2,6-diformyl-4-methylphenol	histamine

**Catecholase activity**

3,5-DTBC


Cat.	$k_{\text{cat}}$ ( $\text{h}^{-1}$ )	$E_a$ (kJ/mole)	Dinuclear moiety	Endogenous bridge ligand	
<b>C6</b>	832	16.3	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(2-aminoethyl)pyrrolidine
<b>C2a</b>	624	24.26	Cu-Cu	2,6-diformyl-4-methylphenol	tryptamine
<b>C8</b>	133	19.7	Cu-Cu	2,6-diacetyl-4-methylphenol	tryptamine
<b>C10</b>	94.5	26.3	Cu-Cu	1,3-diaminopropan-2-ol	2-hydroxy-1-acetonaphthone
<b>C13</b>	45.9	12.9	Cu-Cu	2,6-bis(aminomethyl)-4-nitrophenol	1-hydroxy-2-acetonaphthone
<b>C4</b>	36.8	27.6	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(2-aminoethyl)piperazine
<b>C15</b>	35.01	15.4	Cu-Cu	2,6-bis(aminomethyl)-4-nitrophenol	2-formyl pyrrole
<b>C14</b>	25.38	16.4	Cu-Cu	2,6-bis(aminomethyl)-4-nitrophenol	2-hydroxy-1-acetonaphthone
<b>C5</b>	18.9	30.0	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(2-aminoethyl)morpholine
<b>C3a</b>	17.2	27.55	Cu-Cu	2,6-diformyl-4-methylphenol	histamine
<b>C9</b>	5.81	42.0	Cu-Cu	1,3-diaminopropan-2-ol	1-hydroxy-2-acetonaphthone
<b>C7</b>	3.19	38.0	Cu-Cu	2,6-diacetyl-4-methylphenol	2-picoylamine
<b>C2b</b>	0	0	Cu-Zn	2,6-diformyl-4-methylphenol	tryptamine
<b>C1b</b>	0	0	Cu-Zn	2,6-diformyl-4-methylphenol	pyridoxamine
<b>C3b</b>	0	0	Cu-Zn	2,6-diformyl-4-methylphenol	histamine
<b>C1a</b>	0	0	Cu-Cu	2,6-diformyl-4-methylphenol	pyridoxamine
<b>C16</b>	0	0	Cu-Cu	2,6-bis(aminomethyl)-4-nitrophenol	8-formyl-7-hydroxy-4-methylcoumarin
<b>C12</b>	0	0	Cu-Cu	1,3-diaminopropan-2-ol	8-formyl-7-hydroxy-4-methylcoumarin

## 4-MC


Cat.	$k_{\text{cat}}$ ( $\text{h}^{-1}$ )	$E_a$ (kJ/mole)	Dinuclear moiety	Endogenous bridge ligand	
<b>C10</b>	24.3	37.7	Cu-Cu	1,3-diaminopropan-2-ol	2-hydroxy-1-acetonaphthone
<b>C9</b>	18.7	17.2	Cu-Cu	1,3-diaminopropan-2-ol	1-hydroxy-2-acetonaphthone
<b>C4</b>	16.4	26.7	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(2-aminoethyl)piperazine
<b>C8</b>	14.0	60.1	Cu-Cu	2,6-diacetyl-4-methylphenol	tryptamine
<b>C3a</b>	10.7	31.41	Cu-Cu	2,6-diformyl-4-methylphenol	histamine
<b>C5</b>	8.91	17.7	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(2-aminoethyl)morpholine
<b>C6</b>	6.61	39.1	Cu-Cu	2,6-diacetyl-4-methylphenol	N-(2-aminoethyl)pyrrolidine
<b>C13</b>	4.365	41.9	Cu-Cu	2,6-bis(aminomethyl)-4-nitrophenol	1-hydroxy-2-acetonaphthone
<b>C2a</b>	3.86	30.77	Cu-Cu	2,6-diformyl-4-methylphenol	tryptamine
<b>C7</b>	2.44	18.3	Cu-Cu	2,6-diacetyl-4-methylphenol	2-picoylamine
<b>C2b</b>	0	0	Cu-Zn	2,6-diformyl-4-methylphenol	tryptamine
<b>C1b</b>	0	0	Cu-Zn	2,6-diformyl-4-methylphenol	pyridoxamine
<b>C3b</b>	0	0	Cu-Zn	2,6-diformyl-4-methylphenol	histamine
<b>C1a</b>	0	0	Cu-Cu	2,6-diformyl-4-methylphenol	pyridoxamine
<b>C15</b>	0	0	Cu-Cu	2,6-bis(aminomethyl)-4-nitrophenol	2-formyl pyrrole
<b>C14</b>	0	0	Cu-Cu	2,6-bis(aminomethyl)-4-nitrophenol	2-hydroxy-1-acetonaphthone
<b>C16</b>	0	0	Cu-Cu	2,6-bis(aminomethyl)-4-nitrophenol	8-formyl-7-hydroxy-4-methylcoumarin
<b>C12</b>	0		Cu-Cu	1,3-diaminopropan-2-ol	8-formyl-7-hydroxy-4-methylcoumarin

The following general observations have been made :


- ✚ Homometallic Cu(II)Cu(II) complexes are more active than heterometallic Cu(II)Zn(II)
- ✚ The complexes having imine groups conjugate to phenoxides are more active than those having imine in other part of molecules



**C1-C3 and C4-C8**



**C13-C16**



**C9, C10 and C12**

- ✚ Complexes having nitrogen donors are more active than those having oxygen donor groups. This variation in the activity must be because the conjugation in the phenoxide part of ligands can facilitate the delocalization of electron density over the metal centers through  $\pi$ -bonding. Thus, making Cu(I) to Cu(II) redox easier.
- ✚ The nitrogen donors used in the present study are all having heterocyclic nitrogen, which is a soft ligand, hence facilitating the delocalization of electron density better than the oxygen containing ligands which are relative hard binding sites.
- ✚ The complexes of ligands derived from isomeric acetophenones, and various other complexes are selective towards substrates underlining the fact that the auxiliary groups can play an important role in deciding the selectivity of active sites.

● ● ●